SCHEMBL7124250

SCHEMBL7124250

COc1cccc2c1CCc1cnc(Nc3cccc(-n4ccnc4)c3)nc1-2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.48
PDGFRB P09619 1/20 0.48
BCR P11274 1/20 0.48
SRC P12931 1/20 0.48
PDGFRA P16234 1/20 0.48
PRKCA P17252 1/20 0.48
PRKCD Q05655 1/20 0.48
IGF1R P08069 3/20 0.46
KDR P35968 7/20 0.45
CDK2 P24941 4/20 0.45
CCNA2 P20248 3/20 0.45
PLK1 P53350 3/20 0.45
AURKA O14965 2/20 0.45
CCNA1 P78396 2/20 0.45
SYK P43405 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
IKBKB O14920 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7127974 0.82 IGF1R (0.52) IGF1RKDRCDK2CCNA2PLK1
SCHEMBL7981864 0.81 MAOA (0.41) MAOAMAOB
SCHEMBL7511692 0.79 IGF1R (0.48) IGF1RKDRCDK2CCNA2PLK1
Hydrochloric Acid SCHEMBL7517919 0.79 IGF1R (0.47) IGF1RKDRCDK2CCNA2PLK1
SCHEMBL7239285 0.78 KDR (0.63) PDGFRBIGF1RKDRPLK1PTK2
Hydrochloric Acid SCHEMBL7518134 0.77 KDR (0.62) PDGFRBIGF1RKDRPLK1PTK2
SCHEMBL7510711 0.76 KDR (0.55) IGF1RKDRCDK2CCNA2PLK1
SCHEMBL7128029 0.75 IGF1R (0.48) IGF1RKDRCDK2CCNA2PLK1
Hydrochloric Acid SCHEMBL7512667 0.75 KDR (0.54) IGF1RKDRCDK2CCNA2PLK1
SCHEMBL7510604 0.75 KDR (0.52) IGF1RKDRCDK2CCNA2PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 ABL1 212/4885PDGFRB 2353/4885BCR 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.